Laboratory Corporation of America (Labcorp) has obtained emergency use authorization (EUA) from the US Food and Drug Administration for its combined home collection kit that tests for COVID-19 and influenza A/B simultaneously in patients age two or older.
A rapid at-home test that can differentiate between COVID-19 and influenza offers patients several advantages. Primarily, it can be used to identify those with only flu, who do not need...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?